These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24687462)

  • 1. Atypical femoral fractures in association with bisphosphonate therapy: a case series.
    Rheinboldt M; Harper D; Stone M
    Emerg Radiol; 2014 Oct; 21(5):557-62. PubMed ID: 24687462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
    Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
    Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
    Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
    J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy and atypical fractures.
    Saleh A; Hegde VV; Potty AG; Lane JM
    Orthop Clin North Am; 2013 Apr; 44(2):137-51. PubMed ID: 23544820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dichotomous location of 160 atypical femoral fractures.
    Koeppen VA; Schilcher J; Aspenberg P
    Acta Orthop; 2013 Dec; 84(6):561-4. PubMed ID: 24286566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do we know about atypical femoral fractures? Insights and enigmas.
    Audran M; Cortet B; Thomas T;
    Joint Bone Spine; 2011 Dec; 78(6):568-71. PubMed ID: 21592839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
    Lenart BA; Neviaser AS; Lyman S; Chang CC; Edobor-Osula F; Steele B; van der Meulen MC; Lorich DG; Lane JM
    Osteoporos Int; 2009 Aug; 20(8):1353-62. PubMed ID: 19066707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
    Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS
    Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of subtrochanteric and femoral shaft fractures due to bisphosphonate therapy in asthma: a population-based nested case-control study.
    Chalitsios CV; Shaw DE; McKeever TM
    Osteoporos Int; 2022 Apr; 33(4):931-935. PubMed ID: 34635953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of bisphosphonate-associated femoral fractures.
    Shkolnikova J; Flynn J; Choong P
    ANZ J Surg; 2013 Mar; 83(3):175-81. PubMed ID: 23216704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Femoral insufficiency fractures with bisphosphonate therapy. Cases study.
    Boszczyk A; Kowalski D; Zakrzewski P; Pomianowski S
    Ortop Traumatol Rehabil; 2011; 13(4):403-8. PubMed ID: 21857071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
    Vestergaard P; Schwartz F; Rejnmark L; Mosekilde L
    Osteoporos Int; 2011 Mar; 22(3):993-1001. PubMed ID: 21165600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
    Rizzoli R; Akesson K; Bouxsein M; Kanis JA; Napoli N; Papapoulos S; Reginster JY; Cooper C
    Osteoporos Int; 2011 Feb; 22(2):373-90. PubMed ID: 21085935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical bilateral femoral shaft fracture in patient treated with bisphosphonates.
    Parrón Cambero R; Rey López A; Tomé-Bermejo F; Cibantos Martínez R
    Eur J Orthop Surg Traumatol; 2013 Nov; 23 Suppl 2():S219-23. PubMed ID: 23412218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving data about subtrochanteric fractures and bisphosphonates.
    Shane E
    N Engl J Med; 2010 May; 362(19):1825-7. PubMed ID: 20335574
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral atypical femur fractures without bisphosphonate exposure.
    Szolomayer LK; Ibe IK; Lindskog DM
    Skeletal Radiol; 2017 Feb; 46(2):241-247. PubMed ID: 27900455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical proximal femoral fractures in patients with paget disease receiving bisphosphonate therapy.
    Kilcoyne A; Heffernan EJ
    AJR Am J Roentgenol; 2011 Jul; 197(1):W196-7. PubMed ID: 21700989
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review.
    Warren C; Gilchrist N; Coates M; Frampton C; Helmore J; McKie J; Hooper G
    ANZ J Surg; 2012 Dec; 82(12):908-12. PubMed ID: 22943522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.